--- title: "康方生物首個全球多中心Ⅲ期臨牀研究結果公佈：已達到主要終點" description: "康方生物在世界肺癌大會上公佈了依沃西單抗的全球多中心Ⅲ期臨牀研究 HARMONi 的結果。該研究顯示，經過 13.7 個月的中位隨訪，依沃西單抗聯合化療方案在經三代 EGFR-TKI 治療後疾病進展的患者中，OS 數據顯著改善，尤其在北美人羣中表現突出。依沃西單抗是全球首個 PD-1/VEGF 雙抗藥物，顯示出取代 K 藥的潛力。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/256276815.md" published_at: "2025-09-07T14:03:21.000Z" --- # 康方生物首個全球多中心Ⅲ期臨牀研究結果公佈：已達到主要終點 > 康方生物在世界肺癌大會上公佈了依沃西單抗的全球多中心Ⅲ期臨牀研究 HARMONi 的結果。該研究顯示，經過 13.7 個月的中位隨訪，依沃西單抗聯合化療方案在經三代 EGFR-TKI 治療後疾病進展的患者中，OS 數據顯著改善，尤其在北美人羣中表現突出。依沃西單抗是全球首個 PD-1/VEGF 雙抗藥物，顯示出取代 K 藥的潛力。 9 月 7 日，康方生物依沃西單抗首個全球多中心Ⅲ期臨牀研究 HARMONi 的更新數據在世界肺癌大會上公佈。該研究評估了經三代 EGFR-TKI 治療後疾病進展的患者接受依沃西單抗聯合化療方案的療效與安全性。結果顯示，中位隨訪時間達 13.7 個月，OS 數據明顯改善，北美人羣的生存獲益數據突出。依沃西單抗是全球首個 PD-1/VEGF 雙抗藥物。去年，依沃西單抗在單藥一線治療 PD-L1 陽性非小細胞肺癌的國內註冊性Ⅲ期臨牀研究中，其 PFS 比默沙東的 PD-1 帕博利珠單抗長，顯示出取代 K 藥的潛力。依沃西單抗 “一戰成名”，成為全球最熱門的雙抗。 ### Related Stocks - [09926.HK - 康方生物](https://longbridge.com/zh-HK/quote/09926.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial | Akeso Inc. announced a significant label update for its bispecific antibody, ivonescimab, after approval by China's Nati | [Link](https://longbridge.com/zh-HK/news/271728127.md) | | Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | Akeso, Inc. announced a real-world study presentation at the 2026 ASCO GI Symposium, comparing cadonilimab plus chemothe | [Link](https://longbridge.com/zh-HK/news/272499977.md) | | Akeso Inc. Wins China Approval for Ivonescimab in EGFR-Mutated NSCLC | Akeso Inc. has received regulatory approval from the China National Medical Products Administration for its therapy ivon | [Link](https://longbridge.com/zh-HK/news/264907244.md) | | The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial | Akeso has received FDA approval for a global Phase III trial of cadonilimab in advanced HER2-negative gastric cancer, ma | [Link](https://longbridge.com/zh-HK/news/269971630.md) | | Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study | Akeso Inc. reported that cadonilimab plus chemotherapy outperformed PD-1 inhibitors in a study for first-line treatment | [Link](https://longbridge.com/zh-HK/news/272494568.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。